Trump announces reforms to accelerate access to psychedelic drug treatments
The order opens a pathway for seriously ill patients to access investigational psychedelics and keeps ibogaine scheduled while federal agencies speed review.
- On Saturday, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration to fast-track reviews of breakthrough-designated psychedelic therapies and allocated $50 million in federal funding for private-sector research.
- The order responds to the mental health crisis affecting veterans, with Trump citing the "life-changing potential" of experimental treatments, following Health and Human Services Secretary Robert F. Kennedy Jr.'s criticism of the FDA's "aggressive suppression of psychedelics."
- Shares of Atai Life Sciences and Compass Pathways surged Monday as the order introduces "National Priority Vouchers," potentially cutting FDA review timelines for breakthrough-designated drugs to one or two months from six to 10 months.
- Oppenheimer analyst Jay Olson called the move a "structural inflection" that reduces development risk, while Jefferies analyst Andrew Tsai described it as an "official stamp of validation" signaling government support is "real" and "actionable."
- While the order focuses on ibogaine research, the drug remains a Schedule I substance linked to "cardiovascular toxicity." FDA Commissioner Marty Makary indicated decisions on priority vouchers could arrive this summer, with analysts monitoring potential approvals between 2027 and 2030.
380 Articles
380 Articles
Is Joe Rogan too confident about ibogaine?
On Saturday, Donald Trump signed a major drug-policy executive order directing the fast-tracking of psychedelics such as ibogaine as potential treatments for severe mental health conditions, including addiction and PTSD. Research into novel treatments is important. But so far the evidence supporting the miraculous claims made by advocates such as Joe Rogan — who says [...]Read More...
How Trump's executive order could accelerate widespread access to psychedelic therapies
On Saturday, April 18, President Trump issued an executive order relating to the development of psychedelic substances as medicine. This represents a remarkable moment in the arc of post-1970’s drug policy: We have a Republican administration formally directing federal agencies to accelerate access to psychedelic drugs—including ibogaine, psilocybin, and LSD—as potential treatments for serious mental illnesses like major depressive disorder and …
Is Trump’s order on psychedelics prioritizing health as it promises?
President Donald Trump’s recent executive order authorizing research on psychedelic drugs as mental health treatments has drawn praise for creating increased access to the drugs and pursuing alternative methods of combating America’s mental health crisis. Some, however, are raising concerns that the order isn’t actually putting Americans’ health first.
Executive order on psychedelic-assisted therapies expands on work spearheaded in Texas
HARLINGEN, Texas (ValleyCentral) — After serving as a US Navy SEAL for 13 years, Marcus Capone came home feeling like a different person - and anti-depressants and talk therapy didn't help. “It kind of came to a point where you know, I didn’t want to be here anymore," he said. "I was deeply depressed, there was [...]
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
